M & As this week: RXi Pharmaceuticals, TFS International, Danaher Corporation

RXi Pharmaceuticals plans to expand its product pipeline and enter the immuno-oncology market by acquiring all the outstanding shares of cancer immunotherapies developer MirImmune.

Source: Drug Development Technology - October 13, 2016 Category: Pharmaceuticals Source Type: news